Replies to post #111414 on Biotech Values

[mcbio]

Triple damages if you launch at risk and lose at court.

So it is a real risk, and given NVS's size, not one worth taking unless it is pretty clear cut they are going to win at trial.

Ouch, ok thanks Tinker. Yeah, that's pretty steep so I wouldn't imagine an at-risk launch either given the amount of revenues we would be talking about for a generic Copaxone.

[DewDiligence]

Treble damages are unlikely to be awarded against a company that launches a generic after winning in the US District Court. That’s why I think NVS/MNTA may be willing to launch generic Copaxone after a win in the District Court (assuming they have FDA approval) even if the Appellate Court has not yet ruled.